Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640166 | 0.90 | ESR1 (0.65) | ESR1 | |
| SCHEMBL14622403 | 0.89 | ESR1 (0.65) | ESR1 | |
| SCHEMBL5422500 | 0.89 | ESR1 (0.54) | ESR1ACHEBCHEDRD2DRD4 | |
| SCHEMBL4639764 | 0.89 | ESR1 (0.50) | ESR1ACHEBCHELTA4HKCNH2 | |
| SCHEMBL5623278 | 0.89 | ESR1 (0.52) | ESR1ACHEBCHELTA4HKCNH2 | |
| SCHEMBL5624832 | 0.88 | ESR1 (0.51) | ESR1ACHEBCHELTA4HKCNH2 | |
| SCHEMBL5416865 | 0.88 | ESR1 (0.53) | ESR1ACHEBCHECYP19A1DRD2 | |
| SCHEMBL4729453 | 0.86 | ESR1 (0.55) | ESR1LTA4HKCNH2MCHR1 | |
| SCHEMBL14459769 | 0.85 | ESR1 (0.50) | ESR1LTA4HKCNH2MCHR1 | |
| SCHEMBL6152326 | 0.85 | CYP19A1 (0.51) | ESR1CYP19A1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | NOVARTIS AG (CH) | 2004-05-13 | — | — | US | disclosed |
| US-6620838-B1 | Anticarcinogenic, antimestasis, and antiarthritic agents; osteoporosis and endometriosis treatment | SIGNAL PHARMACEUTICALS, INC. | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | ESR2, CYP19A1, ESRRA | ESR1 4/4885ACHE 911/4885BCHE 1850/4885 |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR2, ESRRA, ESR1 | ESR1 3/4885ACHE 651/4885BCHE 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.